Analyst predicts golden future for GLP-1 as drugmakers rush to join in
Novo Nordisk’s launch of weight-loss drug Wegovy has pushed the market for the medical treatment of chronic diseases like diabetes and obesity.
by dorthe bach, translated by daniel pedersen
A number of pharmaceutical companies have thrown their name in the ring to curb chronic diseases like diabetes and obesity, especially in the aftermath of the success that Danish drugmaker Novo Nordisk has found with Wegovy (semaglutide), writes Danish financial media Finans.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
UBS skeptical of Novo Nordisk's sky-high market valuation
For subscribers
